{"id":"W4226374363","doi":"","title":"Phase I/IIa Trial of BMS-986148, an Anti-mesothelin Antibody-drug Conjugate, Alone or in Combination with Nivolumab in Patients with Advanced Solid Tumors","year":2022,"lang":"en","type":"article","venue":"EUR Research Repository (Erasmus University Rotterdam)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":true,"ca_institutions":"Alberta Cancer Foundation; Princess Margaret Cancer Centre","funders":"Ono Pharmaceutical; Università degli Studi di Milano; Bristol-Myers Squibb","keywords":"Tolerability; Nivolumab; Medicine; Adverse effect; Internal medicine; Dosing; Phases of clinical research; Pharmacology; Gastroenterology; Mesothelin; Pharmacodynamics; Oncology; Clinical trial; Cancer; Pharmacokinetics; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001945773,0.0002966308,0.0008146885,0.001841655,0.0005230487,0.00005156584,0.0006174591,0.00008372088,0.0003929747],"category_scores_gemma":[0.00009423776,0.0002723339,0.00008658752,0.002254242,0.0005210475,0.0005703361,0.0003698835,0.001477925,0.000004874318],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001259049,"about_ca_system_score_gemma":0.001272579,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001803694,"about_ca_topic_score_gemma":0.0004664529,"domain_scores_codex":[0.9930437,0.002158148,0.0005727092,0.0008497399,0.002532282,0.0008434347],"domain_scores_gemma":[0.9975294,0.0002836713,0.0002599491,0.0008758375,0.0007132622,0.0003379129],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6944004,0.02014063,0.1626951,0.0002409364,0.0001731387,0.006453372,0.003025257,0.0004354381,0.1096874,0.00003385366,0.0002776927,0.002436806],"study_design_scores_gemma":[0.7537826,0.0737949,0.1321948,0.0006194157,0.00005773982,0.0001210121,0.006559555,0.00152102,0.02791657,0.00001223115,0.002719659,0.0007004636],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9940899,0.00001973225,0.00001209521,0.0002980882,0.0001028593,0.004064788,0.00004576181,0.00005445298,0.001312327],"genre_scores_gemma":[0.9928795,0.00002906505,0.0001462725,0.00003607833,0.00005334663,0.00002974272,0.0002112784,0.00006845973,0.006546221],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.08177079,"threshold_uncertainty_score":0.9999729,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02240105381484284,"score_gpt":0.3279784093321598,"score_spread":0.3055773555173169,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}